Skip to main content
. 2013 Jun 3;4(9):1322–1332. doi: 10.1021/cn400116z

Figure 6.

Figure 6

Evaluation of antiallodynic effects of MJN110 in rats using the HFD/STZ model of diabetic neuropathy. (A) Fasting plasma glucose in HFD/STZ treated rats (n = 37). All data represent mean ± SEM, analysis was by a repeated measures ANOVA with Dunnett’s multiple comparison posthoc test: ***p < 0.001, compared to baseline (Day −5). (B) Fasting plasma insulin in HFD/STZ treated rats (n = 37). All data represent mean ± SEM, analysis was by Friedman test with Dunn’s posthoc test: *** p < 0.001, compared to baseline (Day −5). (C) Mechanical withdrawal thresholds of the hindpaw in HFD/STZ (45 mg·kg–1) treated rats (n = 36). All data represent mean ± SEM, analysis was by Friedman test with Dunn’s posthoc test: **p < 0.01, ***p < 0.001, compared to baseline (Day −2). (D) Effects of MJN110 (5.0 mg·kg–1, i.p.), URB597 (0.3 mg·kg–1, i.p.) and pregabalin (10 mg·kg–1, p.o.) on mechanical withdrawal thresholds in HFD/STZ treated rats (day 37 post model induction) at 1 and 3 h following drug administration. Data are mechanical withdrawal thresholds expressed as a percentage of baseline values, analysis was with Friedman test with Dunn’s posthoc test: *p < 0.05; **p < 0.01.